LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study

Volume: 32, Pages: S1333 - S1333
Published: Sep 1, 2021
Abstract
Data on perioperative chemotherapy (CTX) in resectable pancreatic cancer (rPDAC) are limited. The NEONAX trial examined perioperative or adjuvant CTX with gemcitabine plus nab-paclitaxel in rPDAC (NCCN...
Paper Details
Title
LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study
Published Date
Sep 1, 2021
Volume
32
Pages
S1333 - S1333
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.